Literature DB >> 21331479

An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

A Carlo Altamura1, Marta Serati, Alessandra Albano, Riccardo A Paoli, Ira D Glick, Bernardo Dell'Osso.   

Abstract

The presence of comorbidity in major psychoses (e.g., schizophrenia and psychotic subtypes of bipolar disorder and major depressive disorder) seems to be the rule rather than the exception in both DSM-IV and ICD-10. Examining comorbidity in major psychoses, however, requires an investigation into the different levels of comorbidity (either full-blown and subsyndromal) which should be analyzed in both psychopathological and medical fields. On one hand, the high prevalence of psychiatric comorbidity in major psychoses may be the result of the current nosographic systems. On the other hand, it may stem from a common neurobiological substrate. In fact, comorbid psychopathological conditions may share a biological vulnerability, given that dysfunction in specific brain areas may be responsible for different symptoms and syndromes. The high rates of comorbidity in major psychoses require targeted pharmacological treatments in order to effectively act on both the primary diagnosis and comorbid conditions. Nevertheless, few controlled trials in comorbid major psychoses had been carried out and treatment recommendations in this field have mostly an empirical basis. The aim of the present article is to provide a comprehensive and updated overview in relation to epidemiological and clinical issues of comorbidity in major psychoses.

Entities:  

Mesh:

Year:  2011        PMID: 21331479     DOI: 10.1007/s00406-011-0196-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  219 in total

Review 1.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.

Authors:  Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2005       Impact factor: 4.132

2.  The increasing medical burden in bipolar disorder.

Authors:  David J Kupfer
Journal:  JAMA       Date:  2005-05-25       Impact factor: 56.272

Review 3.  Medical comorbidity in bipolar disorder: re-prioritizing unmet needs.

Authors:  Roger S McIntyre; Joanna K Soczynska; John L Beyer; Hanna O Woldeyohannes; Candy W Y Law; Andrew Miranda; Jakub Z Konarski; Sidney H Kennedy
Journal:  Curr Opin Psychiatry       Date:  2007-07       Impact factor: 4.741

Review 4.  Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis.

Authors:  Ruth Cunill; Xavier Castells; Daphne Simeon
Journal:  J Clin Psychiatry       Date:  2008-12-02       Impact factor: 4.384

5.  Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression.

Authors:  Kang Sim; Rathi Mahendran; Samuel G Siris; Stephan Heckers; Siow Ann Chong
Journal:  Psychiatry Res       Date:  2004-12-15       Impact factor: 3.222

Review 6.  Physical illness and schizophrenia: a review of the literature.

Authors:  S Leucht; T Burkard; J Henderson; M Maj; N Sartorius
Journal:  Acta Psychiatr Scand       Date:  2007-11       Impact factor: 6.392

7.  Phenomenology and prognostic significance of delusions in major depressive disorder: a 10-year prospective follow-up study.

Authors:  Mario Maj; Raffaele Pirozzi; Lorenza Magliano; Andrea Fiorillo; Luca Bartoli
Journal:  J Clin Psychiatry       Date:  2007-09       Impact factor: 4.384

8.  Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report.

Authors:  P L Herridge; H G Pope
Journal:  J Clin Psychopharmacol       Date:  1985-08       Impact factor: 3.153

Review 9.  Schizophrenia and sudden cardiac death: a review.

Authors:  Hannu Koponen; Antti Alaräisänen; Kaisa Saari; Olavi Pelkonen; Heikki Huikuri; M J Pekka Raatikainen; Markku Savolainen; Matti Isohanni
Journal:  Nord J Psychiatry       Date:  2008       Impact factor: 2.202

10.  Neurocognitive deterioration in elderly chronic schizophrenia patients with and without PTSD.

Authors:  Craig Goodman; Boris Finkel; Mahmud Naser; Piter Andreyev; Yehoshua Segev; Rena Kurs; Yuval Melamed; Avi Bleich
Journal:  J Nerv Ment Dis       Date:  2007-05       Impact factor: 2.254

View more
  14 in total

Review 1.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

2.  The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).

Authors:  Giuseppe Carrà; Sonia Johnson; Paul Bebbington; Matthias C Angermeyer; Dirk Heider; Traolach Brugha; Jean-Michel Azorin; Mondher Toumi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

3.  Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups.

Authors:  Scott W Woods; Albert R Powers; Jerome H Taylor; Charlie A Davidson; Jason K Johannesen; Jean Addington; Diana O Perkins; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

4.  The impact of repeated manic episodes and executive dysfunction on work adjustment in bipolar disorder.

Authors:  C M Bonnín; C Torrent; J M Goikolea; M Reinares; B Solé; M Valentí; J Sánchez-Moreno; D Hidalgo; R Tabarés-Seisdedos; A Martínez-Arán; E Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-08-03       Impact factor: 5.270

5.  Overexpression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder.

Authors:  Cátia M Teixeira; Eduardo D Martín; Ignasi Sahún; Nuria Masachs; Lluís Pujadas; André Corvelo; Carles Bosch; Daniela Rossi; Albert Martinez; Rafael Maldonado; Mara Dierssen; Eduardo Soriano
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

6.  From generation of biomarkers to treatment and psychosocial aspects of psychosis.

Authors:  P Falkai; H-J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-10       Impact factor: 5.270

Review 7.  Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.

Authors:  Matteo Vismara; Beatrice Benatti; Gregorio Nicolini; Ilaria Cova; Edoardo Monfrini; Alessio Di Fonzo; Vincenza Fetoni; Caterina A Viganò; Alberto Priori; Bernardo Dell'Osso
Journal:  BMC Neurol       Date:  2022-05-05       Impact factor: 2.903

Review 8.  Lurasidone for the treatment of bipolar depression: an evidence-based review.

Authors:  Rachel Franklin; Sam Zorowitz; Andrew K Corse; Alik S Widge; Thilo Deckersbach
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-19       Impact factor: 2.570

9.  Monocyte and lymphocyte activation in bipolar disorder: a new piece in the puzzle of immune dysfunction in mood disorders.

Authors:  Izabela Guimarães Barbosa; Natália Pessoa Rocha; Frankcinéia Assis; Érica Leandro Marciano Vieira; Jair C Soares; Moises Evandro Bauer; Antônio Lúcio Teixeira
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

10.  Chemokines in bipolar disorder: trait or state?

Authors:  Izabela Guimarães Barbosa; Natália Pessoa Rocha; Moisés Evandro Bauer; Aline Silva de Miranda; Rodrigo Barreto Huguet; Helton José Reis; Patricia A Zunszain; Mark A Horowitz; Carmine M Pariante; Antônio Lúcio Teixeira
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-15       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.